ABCMdb

ABCC7 p.Ala299Thr

CF databases:	c.895G>A , p.Ala299Thr (CFTR1) ? , Asymptomatic subject.
Predicted by SNAP2:	C: N (57%), D: D (71%), E: D (63%), F: D (66%), G: D (53%), H: D (85%), I: N (72%), K: D (71%), L: D (63%), M: D (53%), N: D (59%), P: D (71%), Q: D (63%), R: D (71%), S: N (78%), T: N (61%), V: N (82%), W: D (91%), Y: D (80%),
Predicted by PROVEAN:	C: N, D: N, E: N, F: N, G: N, H: N, I: N, K: N, L: N, M: N, N: N, P: N, Q: N, R: N, S: N, T: N, V: N, W: N, Y: N,

[switch to compact view]
Comments [show]

None has been submitted yet.

Publications
[hide] [Evaluation of 47,213 infants in neonatal screenin... Arch Pediatr. 2001 Mar;8(3):275-81. Barthellemy S, Maurin N, Roussey M, Ferec C, Murolo S, Berthezene P, Iovanna JL, Dagorn JC, Sarles J
[Evaluation of 47,213 infants in neonatal screening for cystic fibrosis, using pancreatitis-associated protein and immunoreactive trypsinogen assays].
Arch Pediatr. 2001 Mar;8(3):275-81., [PMID:11270251]

Abstract [show]
OBJECTIVES: The increasing evidence of the benefits of neonatal screening for cystic fibrosis (CF) indicates that this procedure could soon be implemented throughout France. The screening strategy currently used involves the detection of infants with elevated levels of immunoreactive trypsinogen (IRT) (approximately 1% of the population), followed by the detection of CFTR gene mutations. However, genetic analysis has certain drawbacks, the most important of which being the management of heterozygotes, and in France the requirement by law of previous informed consent. In cases of CF, pancreatic alterations are already present in utero. A previous study has demonstrated the value of pancreatitis-associated protein (PAP) as a screening test for CF, and has indicated that a feasible two-stage strategy could involve the following: 1) selection of infants with elevated PAP levels; 2) in this group of infants, subsequent detection of those with elevated IRT levels for direct CF diagnosis by the sweat test thereby avoiding the use of genetic analysis. The study aim was to evaluate this strategy in a large number of neonates. METHODS AND RESULTS: The aforementioned strategy was evaluated in a prospective study involving 47,213 infants in the Provence region of France. In infants with a PAP > 7.5 ng/mL (1.28%), 176 had an elevated IRT level > 700 ng/mL (0.37%). In this limited population sample (0.37% of the total), the sweat test diagnosed five cases of CF. A sixth case involving the monozygous twin of an infant with diagnosed CF remained undetected, probably because of a registration error. Genetic analysis confirmed the diagnosis, and also detected another case in an infant with two CFTR mutations but with a normal phenotype at 20 months of age. As the observed incidence was similar to that which had previously been reported, and as no further case was subsequently detected two years after the end of the study, this indicated that the sensitivity of this screening strategy was satisfactory. Its specificity makes the direct diagnosis of CF cases by the sweat test feasible, without further selection by genetic analysis. CONCLUSION: The PAP/IRT technique for CF detection seems to be suitable for mass screening, without the drawbacks of genetic testing.

Comments [show]

None has been submitted yet.

Sentences [show]
No. Sentence Comment
102 Une anomalie non d&#e9;crite &#e0; ce jour (A299T) et dont le r&#f4;le pathologique est incertain a &#e9;galement &#e9;t&#e9; d&#e9;couverte chez un enfant. Login to comment
168 Par ailleurs, 16 enfants h&#e9;t&#e9;rozygotes, dont l`un porteur d`une mutation nouvelle (A299T), ont &#e9;t&#e9; identifi&#e9;s. Login to comment